S&P 500 slips, but losses kept in check as Nvidia climbs ahead of results
Healthpeak Properties (NYSE:DOC), Inc. NASDAQ:DOC Director Scott M. Brinker reported purchasing 2,930 shares of the company’s common stock on July 31, 2025. The shares were bought at a price of $17.06, for a total transaction value of $49,985. The purchase comes as the stock trades near its 52-week low of $16.64, with InvestingPro analysis suggesting the stock is currently undervalued.
Following the transaction, Brinker directly owns 210,416 shares of Healthpeak Properties. The company offers an attractive 7.08% dividend yield and has maintained dividend payments for 41 consecutive years. For deeper insights into Healthpeak Properties’ valuation and 8 additional key metrics, check out the comprehensive Pro Research Report available on InvestingPro.
In other recent news, Healthpeak Properties reported its second-quarter 2025 earnings, revealing mixed results. The company’s earnings per share (EPS) were $0.05, falling short of the anticipated $0.064, a miss of approximately 21.88%. On a positive note, Healthpeak’s revenue slightly exceeded expectations, coming in at $694.35 million compared to the forecasted $689.32 million. Despite the revenue beat, investor concerns were evident following the earnings miss. Scotiabank (TSX:BNS) downgraded Healthpeak Properties from Sector Outperform to Sector Perform, citing weak leasing performance and rising laboratory credit risk concerns. Additionally, Scotiabank adjusted its price target for the company to $19.00. Meanwhile, KeyBanc reiterated its Sector Weight rating for Healthpeak Properties, highlighting ongoing lab occupancy issues impacting the healthcare REIT’s performance. These developments reflect a challenging period for Healthpeak Properties amid broader market dynamics.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.